Flarin logo

Flarin

Startups icon Seedtable Score 44 Startups icon Startups

1

Funding Rounds

1

Investors

$6.3m

Money raised

Overview

Flarin has significant potential due to its patent-protected anti-inflammatory painkiller, offering unique benefits and efficacy in treating pain and inflammation. Based in London and operating on a B2C model, Flarin is accessible to a wide consumer base. Its proprietary formula differentiates it in a crowded market of over-the-counter pain relievers and prescription medications. Backed by ITV AdVentures, Flarin has strong financial support to scale operations and marketing. With the rising demand for effective pain management solutions, Flarin is well-positioned to capture a substantial market share and build a strong brand.
  • Website: https://flarin.co.uk
  • Business model: b2c
  • Company size: 1 - 11 employees
  • Headquarters: London, UK
  • Founded: 2000
  • Social accounts: Linkedin

Unlock Complete Company Intelligence

Access comprehensive data and insights available only to Seedtable members

Financial Details

  • • Complete funding history and valuations
  • • Revenue estimates and financial metrics
  • • Investment round details and terms

People & Contacts

  • • Complete leadership team profiles
  • • Contact information and email addresses
  • • Board members and advisors

Market Intelligence

  • • Competitive landscape analysis
  • • Market position and growth metrics
  • • Industry benchmarking data

Premium Tools

  • • Export data and generate reports
  • • Save companies to custom watchlists
  • • API access for data integration

Join 10,000+ Professionals

Trusted by investors, founders, and analysts worldwide

Access detailed insights on 71,000+ companies worldwide

Investors (1)

ITV AdVentures logo ITV AdVentures

Biotech, Pharma

Details

View all investors.

Join 23,000+ founders, operators and investors.

Funding

Funding series

Funding Series Analysis

The company Flarin has raised a total of $6.3m in funding over 1 rounds.

Key Insights:

  • Series A: $6.3m
Flarin logo
Flarin Series A (2023, $6M) $6.3m